Condition (MeSH)
Nephrocalcinosis
ClinicalTrials.gov lists 20 trials for Nephrocalcinosis or a narrower condition beneath it. Calcilytix Therapeutics, Inc., a BridgeBio company has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
20 of the 20 trials are tagged with Nephrocalcinosis itself; the rest are tagged with a narrower condition beneath it.
When did Nephrocalcinosis trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 3 |
| 2018 | 3 |
| 2015 | 2 |
| 2013 | 1 |
| 2012 | 1 |
| 2005 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Nephrocalcinosis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |
| Not applicable | 2 |
| Observational | 10 |
How many Nephrocalcinosis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 3 |
| Active, not recruiting | 3 |
| Completed | 5 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Nephrocalcinosis trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Calcilytix Therapeutics, Inc., a BridgeBio company | 2 |
| Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 1 |
Which drugs are being tested for Nephrocalcinosis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Encaleret | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Rifampicin | 2 |
| Alkaline citrate | 1 |
| Low dose losartan | 1 |
| Empagliflozine | 1 |
| Fluconazol | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Nephrocalcinosis? (32)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research | 2024 | Yes |
| Renal complications in chronic hypoparathyroidism - a systematic cross-sectional assessment. | Frontiers in endocrinology | 2023 | Yes |
| Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research | 2022 | Yes |
| Fluconazole in hypercalciuric patients with increased 1,25(OH)<sub>2</sub>D levels: the prospective, randomized, placebo-controlled, double-blind FLUCOLITH trial. | Trials | 2022 | Yes |
| [Nephrolithiasis and nephrocalcinosis in children and adolescents]. | Urologie (Heidelberg, Germany) | 2022 | Yes |
Showing 5 of 32 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.